Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146796

Pw146796 View Pathway
drug action

Thiohexam Drug Metabolism Action Pathway

Homo sapiens

PW176357

Pw176357 View Pathway
metabolic

Thiohexam Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW128417

Pw128417 View Pathway
drug action

Thiopental Action Pathway

Homo sapiens
Thiopental is a barbiturate utilized for inducing general anesthesia, managing convulsions, and reducing intracranial pressure. Administered intravenously, this barbiturate is employed to induce general anesthesia promptly, achieve temporary complete anesthesia, induce hypnosis, and control convulsive conditions. Notably, it has been employed in neurosurgical contexts to alleviate elevated intracranial pressure. Although it lacks excitatory effects, its analgesic and muscle relaxant properties are limited. It has been shown that low doses can counteract analgesia and lower the pain threshold. Thiopental finds application as the sole anesthetic for brief procedures, as an induction agent preceding other anesthetics, to supplement regional anesthesia, to provide hypnosis alongside other agents for analgesia or muscle relaxation, for managing convulsions during inhalation or local anesthesia, in neurosurgical cases with heightened intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders. Functioning as an ultrashort-acting central nervous system depressant, thiopental induces rapid hypnosis and anesthesia, yet it lacks analgesic properties. Its binding to a specific site linked to a Cl- ionopore at the GABAA receptor extends the opening duration of the ionopore, thereby prolonging GABA's inhibitory effect in the thalamus. This results in prolonged post-synaptic inhibition. The drug's rapid binding to fatty tissues leads to anesthetic accumulation, producing prolonged effects due to gradual drug release.

PW144715

Pw144715 View Pathway
drug action

Thiopental Drug Metabolism Action Pathway

Homo sapiens

PW146344

Pw146344 View Pathway
drug action

Thioredoxin Drug Metabolism Action Pathway

Homo sapiens

PW123556

Pw123556 View Pathway
metabolic

Thioredoxin Pathway

Pseudomonas aeruginosa
Thioredoxins are a class of proteins that are used in redox reactions, and are found in all living organisms. In humans, they respond to reactive oxygen species, while in plants they are important for growth, photosynthesis, flowering and seed formation. In E. coli, thioredoxins catalyze a number of redox reactions, and are important in stress response, as well as other functions. In this pathway, oxidized thioredoxin is reduced by thioredoxin reductase, in order to form reduced thioredoxin. This reaction also uses NADPH as a cofactor. Reduced thioredoxin then, as part of a redox reaction, acts as the oxidizing agent and converts an oxidized electron acceptor into a reduced electron acceptor. This then produces oxidized thioredoxin, which can be further reduced and reused in other redox reactions.

PW002082

Pw002082 View Pathway
metabolic

Thioredoxin Pathway

Escherichia coli
Thioredoxins are a class of proteins that are used in redox reactions, and are found in all living organisms. In humans, they respond to reactive oxygen species, while in plants they are important for growth, photosynthesis, flowering and seed formation. In E. coli, thioredoxins catalyze a number of redox reactions, and are important in stress response, as well as other functions. In this pathway, oxidized thioredoxin is reduced by thioredoxin reductase, in order to form reduced thioredoxin. This reaction also uses NADPH as a cofactor. Reduced thioredoxin then, as part of a redox reaction, acts as the oxidizing agent and converts an oxidized electron acceptor into a reduced electron acceptor. This then produces oxidized thioredoxin, which can be further reduced and reused in other redox reactions.

PW128159

Pw128159 View Pathway
drug action

Thioridazine Dopamine Antagonist Action Pathway

Homo sapiens
Thioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme. The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity

PW144791

Pw144791 View Pathway
drug action

Thioridazine Drug Metabolism Action Pathway

Homo sapiens

PW128160

Pw128160 View Pathway
drug action

Thioridazine Serotonin Antagonist Action Pathway

Homo sapiens
Thioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme. The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity